Revisiting Interventions in Aseptic Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Revisiting Interventions in Aseptic Processing
The authors revisit their previous effort to refine the terms that describe interventions and to dispel confusion that arose after the original article was published.


Pharmaceutical Technology
Volume 35, Issue 4, pp. 69-72

References

1. J. Agalloco and J. Akers, "Aseptic Processing" supplement to Pharm. Technol. 31 (5), s8–s11 (2007).

2. J. Agalloco and J. Akers, Pharm. Technol. 29 (11), 74–88 (2005).

3. J. Agalloco and J. Akers, Pharm. Technol. 30 (7), 60–76 (2006).

4. J. Agalloco and J. Akers, "Bioprocessing and Sterile Manufacturing" supplement to Pharm. Technol. 34 (3), s44–s45 (2010).

5. J. Akers, J. Agalloco, and R. Madsen, Pharm. Manuf. 4 (2), 25–27 (2006).

6. J. Agalloco and J. Akers, "Aseptic Processing" supplement to Pharm. Technol. 29 (3), s16–s23 (2005).

7. J. Agalloco, J. Akers, and R. Madsen, "The Future of Parenteral Manufacturing," in Pharmaceutical Dosage Forms: Parenteral Medications, Vol. 3, S. Nema and J. Ludwig, Eds. (InformaUSA, New York, 3rd ed., 2010).

8. J. Agalloco and J. Akers, "Future of Aseptic Processing," in Advanced Aseptic Processing Technology, J. Agalloco and J. Akers, Eds. (InformaUSA, New York, 2010).

9. H. Avallone, J. Parenter. Sci. Technol. 43 (1), 3–7 (1989).

*While helping to revise the Parenteral Drug Association's Technical Report (TR) 22, "Process Simulation for Aseptically Filled Products," the authors learned that other task-force members had had similar experiences. The revised TR has a similar perspective on interventions as this article does. The authors provide here a more complete understanding of the problem that resulted from the slightly vague terminology used in their 2007 effort.

**Please note that the text indicates the same rate of intervention, not the same number of interventions.

†Much like the goal for the amount of contamination in aseptic processing simulations, the goal for the number of interventions also should be zero.

††Mandating the removal of a specific number or segment of additional units in the execution of all corrective interventions increases the risk of contamination if that removal requires increased access to the critical zone.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here